Judith Raimbourg

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

Manish A. Shah, Takashi Kojima, Daniel Hochhauser et al. · JAMA Oncology · 2018 · 519 citations · Full text

Medicine, Oncology, Pharmacology +17

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Myriam Delaunay, J. Cadranel, Amélie Lusque et al. · European Respiratory Journal · 2017 · 421 citations · Full text

Medicine, Immunology, Oncology +15

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu et al. · Journal of Thoracic Oncology · 2021 · 322 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

Bert H. O’Neil, John M. Wallmark, David Lorente et al. · PLoS ONE · 2017 · 305 citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Martin Reck, Michael Schenker, Ki Hyeong Lee et al. · European Journal of Cancer · 2019 · 217 citations · Full text

Medicine, Oncology, Pharmacology +17